Emphasis on Drug Type (Specific, Non-specific, Others); Route of Administration (Oral, Parenteral, Others); Application (Pulmonary Hypertension, Erectile Dysfunction, Neurological Diseases, Others); Region/Country
The Phosphodiesterase (PDE) Inhibitors Market was valued at USD 2.82 billion in 2022, growing at a CAGR of 6.1% during the forecast period from 2023 – 2030. Owing to the surge in the poor lifestyle of humans, growing cases of erectile dysfunction, rising geriatric population, and escalating demand for novel drug therapies in the healthcare sector. For instance, according to the World Health Organization (WHO) reports, nearly 150 million people are affected by erectile dysfunction worldwide, and this number is estimated to reach 230 million by 2025. Multiple factors have led to a surge in the market including the availability of next-generation PDE inhibitors, and an increased number of chronic diseases throughout the world. Numerous pharmaceutical companies are competing to develop effective glycopeptide antibiotics for curing prevailing prominent diseases which is also boosting the market growth. For instance, in September 2020, U.S.-based Aspargo Laboratories, Inc. received the international rights to Sildenafil oral spray, the active ingredient in Viagra which is used for the treatment of erectile dysfunction.
Some of the major players operating in the market include Pfizer Inc.; Novartis AG; AbbVie Inc.; Dr. Reddy’s Laboratories Ltd.; Bristol-Myers Squibb Company; GSK plc.; Bayer AG; Teva Pharmaceuticals Industries Ltd.; Lilly; AstraZeneca. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.
Insights Presented in the Report
“Amongst drug type, the specific drug type segment to grow with high CAGR during the forecast period”
Based on drug type, the market is segmented into specific, non-specific, and others. The specific drug type segment is expected to grow with a high CAGR during the forecast period owing to their diversified management and treatment of diseases such as acute decompensated heart failure, benign prostatic hyperplasia, psoriasis, and neonatal apnea. PE3 inhibitors among all specific PDE inhibitors are expected to grow with high CAGR in the forecast period. For instance, Experimental studies reported in the Journal of Experimental Pharmacology in March 2021 indicate a possible role of PDE3, PDE4, PDE5, and PDE7 inhibitors in treating asthma. Thus, amongst drug types, the specific drug type segment is expected to grow with a high CAGR during the forecast period.
“Amongst route of administration, the oral category to grow with high CAGR during the forecast period”
By route of administration, the market is segmented into oral, parenteral, and others. The oral segment is anticipated to grow with significant CAGR during the forecast period majorly due to the convenience offered by oral tablets. Also, they are cost-effective and allow large-scale manufacturing in an easier manner. For instance, the National Library of Medicine reported a survey of patients in September 2022 regarding their preferred mode of administration and they opted for oral tablets every other day. Also, a review article by Frontiers in February 2021 mentioned that around 84% of the best-selling pharmaceutical products are orally administered. Thus, amongst routes of administration, the oral category is expected to grow with high CAGR during the forecast period.
“Amongst application, the erectile dysfunction segment to grow with high CAGR during the forecast period”
Based on application, the market is segmented into pulmonary hypertension, erectile dysfunction, neurological diseases, and others. The erectile dysfunction segment is anticipated to grow with a high CAGR during the forecast period owing to rising cases of cardiovascular diseases, high cholesterol cases, high blood pressure prevalence, diabetes, obesity, and smoking. The rise in erectile dysfunction cases in the population is boosting the growth of this segment in the market. For instance, according to the National Institutes of Health, in 2022, erectile dysfunction (ED) is a very common condition in the U.S. and affects about 30 million men in the country every year. Thus, amongst applications, the erectile dysfunction segment is expected to grow with a high CAGR during the forecast period.
“APAC to grow with high CAGR during the forecast period”
APAC is expected to grow with the highest CAGR during the forecast period. Several factors, such as a rising patient pool, and rising research and development activities are driving the regional market growth. For instance, the Hindustan Times reported in June 2023 that over half of the males under the age of 40 involved in the study had severe erectile dysfunction. Countries such as India and China offer attractive investment opportunities for the PDE-inhibitor market and are anticipated to positively drive demand prospects for phosphodiesterase (PDE) inhibitors. There are bulky investments and collaborations in the APAC region’s pharmaceutical market. These factors would further boost the production of phosphodiesterase (PDE) inhibitors in the APAC region. Thus, APAC is anticipated to grow with a high CAGR during the forecast period.
Phosphodiesterase (PDE) Inhibitors Market Report Coverage
Reasons to buy this report:
Customization Options:
The global phosphodiesterase (PDE) inhibitors market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
1. Market Introduction
2. Research Methodology Or Assumption
3. Market Synopsis
4. Executive Summary
5. Impact Of Covid-19 On The Phosphodiesterase (pde) Inhibitors Market
6. Phosphodiesterase (pde) Inhibitors Market Revenue (usd Bn), 2020-2030f
7. Market Insights By Drug Type
8. Market Insights By Route Of Administration
9. Market Insights By Application
10. Market Insights By Region
11. Phosphodiesterase (pde) Inhibitors Market Dynamics
12. Phosphodiesterase (pde) Inhibitors Market Opportunities
13. Phosphodiesterase (pde) Inhibitors Market Trends
14. Demand And Supply-side Analysis
15. Competitive Scenario
16. Company Profiled
17. Disclaimer
Research Methodology for the Phosphodiesterase (PDE) Inhibitors
Market Analysis (2022-2030)
Analyzing the historical market, estimating the current market, and forecasting the future market of the global phosphodiesterase (PDE) inhibitors market were the three major steps undertaken to create and analyze the adoption of phosphodiesterase (PDE) inhibitors in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global phosphodiesterase (PDE) inhibitors market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
A detailed secondary study was conducted to obtain the historical market size of the phosphodiesterase (PDE) inhibitors market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the phosphodiesterase (PDE) inhibitors market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as drug type, route of administration, application, and region. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the phosphodiesterase (PDE) inhibitors market. Further, we conducted factor analysis using dependent and independent variables such as drug type, route of administration, application, and region of the phosphodiesterase (PDE) inhibitors market. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the phosphodiesterase (PDE) inhibitors market sector across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global phosphodiesterase (PDE) inhibitors market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2030 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global phosphodiesterase (PDE) inhibitors market. data was split into several segments & sub-segments post studying various parameters and trends in the areas of the drug type, route of administration, application, and region in the global phosphodiesterase (PDE) inhibitors market.
The main Objective of the Global Phosphodiesterase (PDE) Inhibitors Market Study
The current & future market trends of the global phosphodiesterase (PDE) inhibitors market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
